Physician profile
Zeinab Moubadder
NPI 1164012720
$808.78
in general payments reported to CMS, 2019-2025
12 companies · $44.94 in 2025
The $44.94 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $328 · 2023: $22.02 · 2024: $165 · 2025: $44.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $150.59 | 2022 | |
| Organogenesis INC. | $125.00 | 2021 | |
| Stability Biologics, LLC | $123.70 | 2021 | |
| Triad Life Sciences INC. | $109.13 | 2022 | |
| Bioventus LLC | $68.28 | 2022 | |
| Paratek Pharmaceuticals, INC. | $59.45 | 2024 | Nuzyra |
| Averitas Pharma INC. | $45.71 | 2024 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $44.90 | 2023-2024 | Saphnelo |
| Globus Medical, INC. | $23.05 | 2025 | Senza |
| Omeza LLC | $22.92 | 2024 | |
| Alexion Pharmaceuticals, INC. | $21.89 | 2025 | Ultomiris |
| Trice Medical, INC. | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeinab Moubadder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.